Goldman resumed coverage on Roivant Sciences with a new price target
$ROIV
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman resumed coverage of Roivant Sciences with a rating of Buy and set a new price target of $19.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2025 | $16.00 | Buy | Citigroup |
| 7/10/2025 | $19.00 | Buy | Goldman |
| 2/15/2024 | $17.00 | Outperform | Wolfe Research |
| 1/5/2024 | $20.00 | Overweight | Piper Sandler |
| 12/12/2023 | $14.00 | Buy | Deutsche Bank |
| 10/17/2023 | $17.00 | Buy | Guggenheim |
| 6/8/2023 | $10.50 | Neutral | BofA Securities |
| 10/27/2022 | $7.00 | Overweight | JP Morgan |
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in dermatomyositisIf approved, brepocitinib would represent the first targeted therapy approved for dermatomyositis DURHAM, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. The FDA has assigned a Prescription Drug User Fee
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00
Goldman resumed coverage of Roivant Sciences with a rating of Buy and set a new price target of $19.00
Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou
NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)